Ansa Biotechnologies 新闻与活动
高管
查看带有其 14 名主要高管的组织结构图
Ansa Biotechnologies 搜索最多的简介
- Jason Gammack, Chief Executive Officer
- Matthew McManus, Chairman of the Board
- Nick Hurt, General Counsel and Head of Intellectual Property
创建提醒
跟踪 Ansa Biotechnologies 的高管变动
生物技术
Ansa Biotechnologies 拥有 2,350 家竞争者，其中包括 Incyte (美国(美洲))、Anthos Therapeutics (美国(美洲)) 和 Valneva (法国)。
Popular M&A news in 生物技术
- CoRegen 刚刚宣布为 93 筹款数百万美元。 (公布2025七月11号).
- Actithera 刚刚宣布为 75 筹款数百万美元。 (公布2025七月10号).
- Centivax 刚刚宣布为 45 筹款数百万美元。 (公布2025七月10号).
生物技术 行业的其他推荐联系人
消息
Ansa Biotechnologies 的最新新闻稿
- Ansa Biotechnologies Sets New Standard in Long, Complex DNA
- News & Events | Ansa Biotechnologies - Page 4
- Enzymatic DNA Synthesis: Shorter Waits, Longer Strands
- Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products
- Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conference
- Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis
- Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences
- DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions
- Ansa Biotechnologies Announces First Shipments of Complex Clonal DNA Sequences to Customers in its Early Access Program
- Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases
- View more press releases Close
